T-DXd and the DESTINY-Breast12 Trial for HER2+ Advanced BC With or Without Brain Mets

Panelists discuss the DESTINY-Breast12 trial, reviewing its study design, rationale, and key efficacy and safety findings in HER2-positive metastatic breast cancer patients with brain metastases, focusing on differences in outcomes between patients with active vs stable brain metastases, and the role of trastuzumab deruxtecan (T-DXd) in expanding treatment options for this patient population.

EP: 1.Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets

EP: 2.Clinical Approaches in Treating HER2+ Breast Cancer and Brain Metastases

Now Viewing

EP: 3.T-DXd and the DESTINY-Breast12 Trial for HER2+ Advanced BC With or Without Brain Mets

Video content above is prompted by the following:

Briefly review the recent findings from the DESTINY-Breast12 trial, highlighting study design, rationale, and key efficacy and safety data in patients with HER2+ mBC and BM.
How do the results differ between patients with and without baseline brain metastases, as well as those with active vs stable brain metastases?
What role does trastuzumab deruxtecan (T-DXd) play in this treatment setting, and how do the trial findings expand its use in HER2-positive breast cancer with central nervous system involvement?